Besides, the combination of MEK inhibitor PD901 and JQ1 has a more significant inhibition on the expression of several ETS factors (ELK3, ETV1, ETV4, ETV5) than MEK inhibitor alone in lung cancer (79). Here, MAP2K7 is linked to lung cancer.